(3E)-2,4-dichloropenta-1,3-diene

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 英文名称: (3E)-2,4-dichloropenta-1,3-diene
• 化学式: C₅H₆Cl₂
• 分子量: 137.0
• InChiKey: RIEMIAZCQPDZQG-HWKANZROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP)<br/>[FR] PETITES MOLÉCULES INHIBITRICES DU PORE DE TRANSITION DE PERMÉABILITÉ MITOCHONDRIALE (MTPTP)
  申请人：UNIV KANSAS

  公开号：WO2016073633A1

  公开（公告）日：2016-05-12

  The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

  目前的技术涉及到本文描述的任一式I、II、IIa、III、IV和/或V的化合物，以及它们的互变异构体和/或药用盐、组合物以及使用方法。
• [EN] 1,2,3,5-TETRAHYDROIMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF DISEASES AND DISORDERS MEDIATED BY LP-PLA2<br/>[FR] DÉRIVÉS 1,2,3,5-TÉTRAHYDRO-IMIDAZO [1,2-C]PYRIMIDINE UTILES POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES MÉDIÉS PAR LA LP-PLA2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2016012917A1

  公开（公告）日：2016-01-28

  The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases or disorders associated with the activity of Lp-PLA2.

  本发明涉及抑制Lp-PLA2活性的新化合物，其制备方法，含有这些化合物的组合物，以及它们在治疗与Lp-PLA2活性相关的疾病或紊乱中的应用。
• [EN] PHENYL mTORC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE MTORC PHÉNYLE ET LEURS UTILISATIONS
  申请人：NAVITOR PHARM INC

  公开号：WO2018089433A1

  公开（公告）日：2018-05-17

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用相同的方法。
• [EN] COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY<br/>[FR] COMPOSÉS INHIBANT L'ACTIVITÉ ENZYMATIQUE DE LA KINASE À RÉPÉTITIONS RICHES EN LEUCINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015026683A1

  公开（公告）日：2015-02-26

  The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及氮杂吲哚化合物，这些化合物是LRRK2激酶的有效抑制剂，并且在治疗或预防LRRK2激酶参与的疾病，如帕金森病中有用。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗LRRK2激酶参与的疾病中使用这些化合物和组合物。
• [EN] COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY<br/>[FR] COMPOSÉS INHIBANT L'ACTIVITÉ ENZYMATIQUE DE LA KINASE À SÉQUENCE RÉPÉTÉE RICHE EN LEUCINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014137719A1

  公开（公告）日：2014-09-12

  The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及一种对LRRK2激酶具有很强抑制作用的吲唑啉化合物，可用于治疗或预防LRRK2激酶参与的疾病，如帕金森病。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗LRRK2激酶参与的疾病中使用这些化合物和组合物。